$RPRX
Royalty Pharma plc

2022 Q2 Form 10-Q Financial Statement

#000180276822000035 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2021 Q4 2021 Q2
Revenue $536.0M $575.7M $555.0M
YoY Change -3.43% 0.63% 8.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $51.84M $46.16M $44.92M
YoY Change 15.41% -7.86% 4.96%
% of Gross Profit
Research & Development $600.0K $103.8M $3.100M
YoY Change -80.65% 1231.04% -46.33%
% of Gross Profit
Depreciation & Amortization $0.00 $5.796M $5.733M
YoY Change -100.0% -0.07% 0.58%
% of Gross Profit
Operating Expenses $600.0K $422.3M $3.100M
YoY Change -80.65% 63.61% -46.33%
Operating Profit $377.8M $744.9M
YoY Change -49.29% 81.99%
Interest Expense $46.97M -$94.93M $37.43M
YoY Change 25.49% -268.31% 9.47%
% of Operating Profit 12.43% 5.02%
Other Income/Expense, Net $113.8M -$4.820M $61.81M
YoY Change 84.13% -401.25% -67.91%
Pretax Income $491.6M $53.67M $806.8M
YoY Change -39.06% -85.36% 34.02%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0% 0.0% 0.0%
Net Earnings $304.5M $7.904M $440.8M
YoY Change -30.92% -95.38% -0.29%
Net Earnings / Revenue 56.82% 1.37% 79.42%
Basic Earnings Per Share $0.70 $1.08
Diluted Earnings Per Share $0.70 $18.32K $1.08
COMMON SHARES
Basic Shares Outstanding 436.3M shares 409.3M shares
Diluted Shares Outstanding 607.2M shares 607.2M shares

Balance Sheet

Concept 2022 Q2 2021 Q4 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.472B $1.607B $1.211B
YoY Change 104.11% 48.99% -51.01%
Cash & Equivalents $2.108B $1.541B $1.142B
Short-Term Investments $363.7M $66.00M $68.70M
Other Short-Term Assets $67.12M $6.631M $12.10M
YoY Change 454.79% -22.86% -5.4%
Inventory
Prepaid Expenses
Receivables $18.03M $53.29M $34.14M
Other Receivables $17.32M $15.02M $10.69M
Total Short-Term Assets $3.504B $2.878B $2.707B
YoY Change 29.41% 6.72% -20.15%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $412.1M $435.4M $465.6M
YoY Change -11.5% -4.3% 8.21%
Other Assets $33.41M $4.145M $5.960M
YoY Change 460.6% -58.54%
Total Long-Term Assets $14.24B $14.64B $13.81B
YoY Change 3.11% 9.86% 12.3%
TOTAL ASSETS
Total Short-Term Assets $3.504B $2.878B $2.707B
Total Long-Term Assets $14.24B $14.64B $13.81B
Total Assets $17.74B $17.52B $16.51B
YoY Change 7.42% 9.34% 5.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.18M $5.620M $9.393M
YoY Change 29.62% -48.91% -72.37%
Accrued Expenses $54.16M $57.70M $152.9M
YoY Change -64.58% -62.04% 36.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $182.3M $171.3M $284.0M
YoY Change -35.8% -44.38% -37.03%
LONG-TERM LIABILITIES
Long-Term Debt $7.106B $7.096B $5.826B
YoY Change 21.98% 22.0% 1.67%
Other Long-Term Liabilities $43.70M $0.00
YoY Change
Total Long-Term Liabilities $7.106B $7.096B $5.826B
YoY Change 21.98% 22.0% -0.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $182.3M $171.3M $284.0M
Total Long-Term Liabilities $7.106B $7.096B $5.826B
Total Liabilities $7.332B $7.267B $6.110B
YoY Change 20.01% 18.66% -2.88%
SHAREHOLDERS EQUITY
Retained Earnings $2.446B $2.255B $2.292B
YoY Change 6.73% 17.42% 45.86%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.752M $2.715M $2.662M
YoY Change 3.38% 17.18% 25.63%
Treasury Stock Shares
Shareholders Equity $6.027B $5.777B $5.734B
YoY Change
Total Liabilities & Shareholders Equity $17.74B $17.52B $16.51B
YoY Change 7.42% 9.34% 5.29%

Cashflow Statement

Concept 2022 Q2 2021 Q4 2021 Q2
OPERATING ACTIVITIES
Net Income $304.5M $7.904M $440.8M
YoY Change -30.92% -95.38% -0.29%
Depreciation, Depletion And Amortization $0.00 $5.796M $5.733M
YoY Change -100.0% -0.07% 0.58%
Cash From Operating Activities $575.0M $490.0M $531.7M
YoY Change 8.13% -13.37% 8.74%
INVESTING ACTIVITIES
Capital Expenditures -$175.0M -$171.7M -$180.6M
YoY Change -3.12% -78.67% -61.99%
Acquisitions
YoY Change
Other Investing Activities $144.8M -$379.9M $306.8M
YoY Change -52.79% 1291.62% 35.76%
Cash From Investing Activities -$30.18M -$551.6M $126.2M
YoY Change -123.92% -33.73% -150.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -228.3M -198.1M -224.4M
YoY Change 1.72% -28.6% -114.21%
NET CHANGE
Cash From Operating Activities 575.0M 490.0M 531.7M
Cash From Investing Activities -30.18M -551.6M 126.2M
Cash From Financing Activities -228.3M -198.1M -224.4M
Net Change In Cash 316.5M -259.8M 433.5M
YoY Change -26.99% -52.27% -76.17%
FREE CASH FLOW
Cash From Operating Activities $575.0M $490.0M $531.7M
Capital Expenditures -$175.0M -$171.7M -$180.6M
Free Cash Flow $750.0M $661.7M $712.4M
YoY Change 5.28% -51.73% -26.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001802768
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39329
dei Entity Registrant Name
EntityRegistrantName
Royalty Pharma plc
CY2021Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.17
CY2022Q1 rprx Long Term Funding Partnership Initial Payment
LongTermFundingPartnershipInitialPayment
50000000 usd
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1535773
dei Entity Address Address Line1
EntityAddressAddressLine1
110 East 59th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
138600000 usd
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10022
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
883-0200
dei Security12b Title
Security12bTitle
Class A ordinary shares, par value $0.0001
dei Trading Symbol
TradingSymbol
RPRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2108037000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1541048000 usd
CY2022Q2 us-gaap Trading Securities Debt
TradingSecuritiesDebt
290402000 usd
CY2021Q4 us-gaap Trading Securities Debt
TradingSecuritiesDebt
581872000 usd
CY2022Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
639244000 usd
CY2021Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
614351000 usd
CY2022Q2 rprx Accrued Royalty Receivable
AccruedRoyaltyReceivable
18032000 usd
CY2021Q4 rprx Accrued Royalty Receivable
AccruedRoyaltyReceivable
53286000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
363700000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
66000000 usd
CY2022Q2 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
17315000 usd
CY2021Q4 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
15023000 usd
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
67119000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
6631000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
3503849000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2878211000 usd
CY2022Q2 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
13423629000 usd
CY2021Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
13718245000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5670000 usd
CY2022Q2 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
304447000 usd
CY2021Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
269800000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
63000000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
204400000 usd
CY2022Q2 us-gaap Equity Method Investments
EquityMethodInvestments
412076000 usd
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
435394000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33412000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4145000 usd
CY2022Q2 us-gaap Assets
Assets
17740413000 usd
CY2021Q4 us-gaap Assets
Assets
17515865000 usd
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
115990000 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
107934000 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
12175000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5620000 usd
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
54162000 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
57696000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
182327000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
171250000 usd
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7106199000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7096070000 usd
CY2022Q2 us-gaap Other Liabilities
OtherLiabilities
43700000 usd
CY2021Q4 us-gaap Other Liabilities
OtherLiabilities
0 usd
CY2022Q2 us-gaap Liabilities
Liabilities
7332226000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
7267320000 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2022Q2 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2022Q2 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
365302000 shares
CY2022Q2 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
365302000 shares
CY2021Q4 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
361170000 shares
CY2021Q4 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
361170000 shares
CY2022Q2 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 usd
CY2021Q4 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3570585000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3507533000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2446132000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2255179000 usd
CY2022Q2 us-gaap Minority Interest
MinorityInterest
4380938000 usd
CY2021Q4 us-gaap Minority Interest
MinorityInterest
4471951000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
13177000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
16491000 usd
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
2752000 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2715000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10408187000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10248545000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17740413000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17515865000 usd
CY2022Q2 us-gaap Revenues
Revenues
535955000 usd
CY2021Q2 us-gaap Revenues
Revenues
554963000 usd
us-gaap Revenues
Revenues
1098004000 usd
us-gaap Revenues
Revenues
1127990000 usd
CY2022Q2 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
105714000 usd
CY2021Q2 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
-243762000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
290335000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
48499000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
606000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3122000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101106000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5763000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5733000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5670000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11404000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
51843000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44921000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
103383000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
88077000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
158163000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
-189986000 usd
us-gaap Costs And Expenses
CostsAndExpenses
500494000 usd
us-gaap Costs And Expenses
CostsAndExpenses
153743000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
377792000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
744949000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
597510000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
974247000 usd
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
737000 usd
CY2021Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
17701000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1134000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
15783000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
46966000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
37426000 usd
us-gaap Interest Expense
InterestExpense
94029000 usd
us-gaap Interest Expense
InterestExpense
74841000 usd
CY2022Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
71805000 usd
CY2021Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1909000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
71805000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-4464000 usd
CY2022Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
8024000 usd
CY2021Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
55495000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-28138000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1309000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
70321000 usd
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
14015000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
53742000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
23130000 usd
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
10919000 usd
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
14037000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
20448000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
30635000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1035000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-107000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2792000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-65000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
113805000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
61806000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22170000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8513000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
491597000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
806755000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
619680000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
965734000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
491597000 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
806755000 usd
us-gaap Profit Loss
ProfitLoss
619680000 usd
CY2022Q2 rprx Long Term Funding Partnership Additional Payments Aggregate Amount
LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
200000000 usd
us-gaap Profit Loss
ProfitLoss
965734000 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
187093000 usd
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
365979000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
263415000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
455839000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
304504000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
440776000 usd
us-gaap Net Income Loss
NetIncomeLoss
356265000 usd
us-gaap Net Income Loss
NetIncomeLoss
509895000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.28
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.70
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.25
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
436318000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
409344000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
435144000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
399606000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607214000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607163000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607207000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607151000 shares
CY2022Q2 us-gaap Profit Loss
ProfitLoss
491597000 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
806755000 usd
us-gaap Profit Loss
ProfitLoss
619680000 usd
us-gaap Profit Loss
ProfitLoss
965734000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9325000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6025000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10950000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11150000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
7988000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
13299000 usd
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
16942000 usd
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
28790000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1337000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7274000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5992000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17640000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
492934000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
799481000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
613688000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
948094000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
187638000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
362748000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
260948000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
447727000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
305296000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
436733000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
352740000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
500367000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10141879000 usd
CY2022Q2 rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
2881000 usd
CY2022Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
146967000 usd
CY2022Q2 us-gaap Dividends Cash
DividendsCash
83049000 usd
CY2022Q2 us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
509000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
491597000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9325000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
7988000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10408187000 usd
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9837033000 usd
CY2021Q2 rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
11519000 usd
CY2021Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
170808000 usd
CY2021Q2 us-gaap Dividends Cash
DividendsCash
72581000 usd
CY2021Q2 us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
721000 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
806755000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6025000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
13299000 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10405365000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10248545000 usd
rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
6203000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
295942000 usd
us-gaap Dividends Cash
DividendsCash
165312000 usd
us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1005000 usd
us-gaap Profit Loss
ProfitLoss
619680000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10950000 usd
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
16942000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10408187000 usd
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9895815000 usd
rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
14772000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
316186000 usd
us-gaap Dividends Cash
DividendsCash
138564000 usd
us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1434000 usd
us-gaap Profit Loss
ProfitLoss
965734000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11150000 usd
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
28790000 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10405365000 usd
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
1181354000 usd
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
1094094000 usd
rprx Long Term Funding Partnership Expected Payment
LongTermFundingPartnershipExpectedPayment
125000000 usd
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
71377000 usd
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
75200000 usd
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
32716000 usd
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
14088000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
27502000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
22003000 usd
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
3262000 usd
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
2332000 usd
rprx Proceeds From Collateral Received On Derivative Instruments
ProceedsFromCollateralReceivedOnDerivativeInstruments
0 usd
rprx Proceeds From Collateral Received On Derivative Instruments
ProceedsFromCollateralReceivedOnDerivativeInstruments
11470000 usd
rprx Payments For Collateral Posted On Derivative Instruments
PaymentsForCollateralPostedOnDerivativeInstruments
0 usd
rprx Payments For Collateral Posted On Derivative Instruments
PaymentsForCollateralPostedOnDerivativeInstruments
9340000 usd
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
1106000 usd
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
5763000 usd
CY2022Q1 rprx Long Term Funding Partnership Amount
LongTermFundingPartnershipAmount
300000000 usd
rprx Payments For Upfront Development Stage Funding
PaymentsForUpfrontDevelopmentStageFunding
100000000 usd
rprx Payments For Upfront Development Stage Funding
PaymentsForUpfrontDevelopmentStageFunding
0 usd
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
93003000 usd
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
81764000 usd
us-gaap Interest Paid Net
InterestPaidNet
86880000 usd
us-gaap Interest Paid Net
InterestPaidNet
64500000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1035222000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1057820000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
0 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
523000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
3050000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
17427000 usd
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
62785000 usd
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
0 usd
rprx Proceeds From Issuance Of Equity Securities Fnni
ProceedsFromIssuanceOfEquitySecuritiesFNNI
0 usd
rprx Proceeds From Issuance Of Equity Securities Fnni
ProceedsFromIssuanceOfEquitySecuritiesFNNI
109367000 usd
CY2022Q1 rprx Long Term Funding Partnership Number Of Tranches
LongTermFundingPartnershipNumberOfTranches
5 tranche
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
79158000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
35170000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
31250000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
31250000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
234869000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
728025000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
525907000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
868689000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
175093000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
683741000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
21215000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 usd
rprx Payments For Milestones
PaymentsForMilestones
0 usd
rprx Payments For Milestones
PaymentsForMilestones
18600000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19013000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-473134000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P1Y
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
215543000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
238197000 usd
rprx Payments To Noncontrolling Interests Other
PaymentsToNoncontrollingInterestsOther
72343000 usd
rprx Payments To Noncontrolling Interests Other
PaymentsToNoncontrollingInterestsOther
86978000 usd
rprx Payment Of Dividends To Shareholders
PaymentOfDividendsToShareholders
165312000 usd
rprx Payment Of Dividends To Shareholders
PaymentOfDividendsToShareholders
138564000 usd
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
731000 usd
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
4080000 usd
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
3247000 usd
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
8574000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-449220000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-451085000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
566989000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
133601000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1541048000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1008680000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2108037000 usd
CY2022Q2 rprx Long Term Funding Partnership Additional Payments Aggregate Amount
LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
200000000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1142281000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co., Pfizer, Astellas, Novartis, and Gilead.
CY2022Q2 rprx Long Term Funding Partnership Covenant Required Amount
LongTermFundingPartnershipCovenantRequiredAmount
50000000 usd
CY2022Q2 rprx Long Term Funding Partnership Installment Repayments Amount Drawn Multiple
LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple
1.9
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
269359000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
113641000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
383000000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
363700000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
63000000 usd
CY2022Q2 rprx Debt Securities Available For Sale Liability Current
DebtSecuritiesAvailableForSaleLiabilityCurrent
0 usd
CY2022Q2 rprx Debt Securities Available For Sale Liability Noncurrent
DebtSecuritiesAvailableForSaleLiabilityNoncurrent
-43700000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
383000000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
204509000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
65891000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
270400000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
66000000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
204400000 usd
CY2021Q4 rprx Debt Securities Available For Sale Liability Current
DebtSecuritiesAvailableForSaleLiabilityCurrent
0 usd
CY2021Q4 rprx Debt Securities Available For Sale Liability Noncurrent
DebtSecuritiesAvailableForSaleLiabilityNoncurrent
0 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
270400000 usd
CY2022Q2 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
8000000 usd
us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
-28100000 usd
CY2021Q2 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
28300000 usd
us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
-10700000 usd
CY2021Q4 rprx Debt Securities Available For Sale Restriction Period
DebtSecuritiesAvailableForSaleRestrictionPeriod
P6M
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 usd
CY2022Q2 us-gaap Notes Receivable Gross
NotesReceivableGross
16048153000 usd
CY2022Q2 rprx Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
1737435000 usd
CY2022Q2 rprx Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
14310718000 usd
CY2022Q2 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
247845000 usd
CY2022Q2 us-gaap Notes Receivable Net
NotesReceivableNet
14062873000 usd
CY2021Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
16027541000 usd
CY2021Q4 rprx Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
1384141000 usd
CY2021Q4 rprx Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
14643400000 usd
CY2021Q4 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
310804000 usd
CY2021Q4 us-gaap Notes Receivable Net
NotesReceivableNet
14332596000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
606216000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
600546000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5670000 usd
CY2021Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
1694945000 usd
rprx Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense
FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense
556020000 usd
rprx Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense
FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
202726000 usd
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
-62959000 usd
CY2022Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
1985280000 usd
CY2021Q4 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
310800000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
606216000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
606216000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
600000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101100000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3100000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5800000 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
193801000 usd
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
203930000 usd
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
7106199000 usd
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
7096070000 usd
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7106199000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7096070000 usd
CY2022Q2 rprx Number Of Classes Of Voting Stock
NumberOfClassesOfVotingStock
2 class
CY2022Q2 rprx Common Stock Voting Rights Number Of Votes
CommonStockVotingRightsNumberOfVotes
1 vote
CY2022Q2 rprx Common Stock Quarterly Conversion Basis
CommonStockQuarterlyConversionBasis
1 shares
CY2022Q2 rprx Number Of Noncontrolling Interests
NumberOfNoncontrollingInterests
4 noncontrolling_interest
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.19
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
165300000 usd
CY2022Q2 rprx Common Stock Exchange Ratio
CommonStockExchangeRatio
1
CY2022Q2 us-gaap Profit Loss
ProfitLoss
491597000 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
806755000 usd
us-gaap Profit Loss
ProfitLoss
619680000 usd
us-gaap Profit Loss
ProfitLoss
965734000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
304504000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
440776000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
356265000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
509895000 usd
CY2022Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
119224000 usd
CY2021Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
212961000 usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
139886000 usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
251506000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
423728000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
653737000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
496151000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
761401000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
436318000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
409344000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
435144000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
399606000 shares
CY2022Q2 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
170864000 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
197773000 shares
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
172035000 shares
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
207508000 shares
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
32000 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
46000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
28000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
37000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607214000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607163000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607207000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607151000 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.28
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.70
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.25
us-gaap Profit Loss
ProfitLoss
619680000 usd
us-gaap Profit Loss
ProfitLoss
965734000 usd
rprx Increase Decrease In Financial Royalty Assets
IncreaseDecreaseInFinancialRoyaltyAssets
1026873000 usd
rprx Increase Decrease In Financial Royalty Assets
IncreaseDecreaseInFinancialRoyaltyAssets
1033039000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
290335000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
48499000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5670000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11404000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
10683000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
9583000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
71805000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-4464000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-28138000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1309000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1134000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
15783000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
27502000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
22003000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1005000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1434000 usd
rprx Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss
InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
16942000 usd
rprx Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss
InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
28790000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
53742000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
23130000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2657000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2049000 usd
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
1181354000 usd
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
1094094000 usd
rprx Increase Decrease In Accrued Royalty Receivable
IncreaseDecreaseInAccruedRoyaltyReceivable
-35254000 usd
rprx Increase Decrease In Accrued Royalty Receivable
IncreaseDecreaseInAccruedRoyaltyReceivable
988000 usd
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
2292000 usd
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
4683000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2711000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-3703000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6555000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-913000 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-3534000 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
758000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
0 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
2730000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1035222000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1057820000 usd
CY2022Q2 rprx Long Term Funding Commitment Amount Outstanding
LongTermFundingCommitmentAmountOutstanding
250000000 usd
CY2022Q2 rprx Long Term Funding Partnership Covenant Required Amount
LongTermFundingPartnershipCovenantRequiredAmount
50000000 usd
CY2022Q2 rprx Long Term Funding Partnership Additional Payments Aggregate Amount
LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
200000000 usd
rprx Long Term Funding Partnership Expected Payment
LongTermFundingPartnershipExpectedPayment
125000000 usd
CY2022Q2 rprx Long Term Funding Partnership Additional Payments Aggregate Amount
LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
200000000 usd
CY2022Q2 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
115990000 usd
CY2021Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
107934000 usd

Files In Submission

Name View Source Status
0001802768-22-000035-index-headers.html Edgar Link pending
0001802768-22-000035-index.html Edgar Link pending
0001802768-22-000035.txt Edgar Link pending
0001802768-22-000035-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rprx-20220630.htm Edgar Link pending
rprx-20220630.xsd Edgar Link pending
rprx-20220630ex311.htm Edgar Link pending
rprx-20220630ex312.htm Edgar Link pending
rprx-20220630ex32.htm Edgar Link pending
rprx-20220630_cal.xml Edgar Link unprocessable
rprx-20220630_def.xml Edgar Link unprocessable
rprx-20220630_htm.xml Edgar Link completed
rprx-20220630_lab.xml Edgar Link unprocessable
rprx-20220630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending